Total Funding
1
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
4087231
Transition Therapeutics is a biopharmaceutical company developing novel therapeutics for disease indications with large markets.
Bruce Connop: Vice President of Nonclinical & Pharmaceutical Development
Tony Cruz: Founder & Chief Executive OfficerPast Role: Canadian Arthritis Network, President & CEO
About the Company
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 for the treatment of Alzheimer's disease and TT223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and
developed internally using its proprietary drug discovery engine.
